...
首页> 外文期刊>Indian journal of dermatology, venereology and leprology >Evening primrose oil is effective in atopic dermatitis: a randomized placebo-controlled trial.
【24h】

Evening primrose oil is effective in atopic dermatitis: a randomized placebo-controlled trial.

机译:月见草油对特应性皮炎有效:随机安慰剂对照试验。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Atopic dermatitis (AD) is a chronic, relapsing, itchy dermatosis of multifactorial origin, which commonly starts in childhood. Defective metabolism of essential fatty acids leading to relative dominance of pro-inflammatory prostaglandins (PGE2 and PGF2) has been reported as an important factor in the pathogenesis of AD. Evening primrose oil (EPO) as a source of gamma-linolenic acid (GLA) has been of interest in the management of AD. AIM: To evaluate the efficacy and safety of EPO in atopic dermatitis in our patients. METHODS: Consecutive new out-patient department (OPD) patients of a referral hospital in Kolkata clinically diagnosed as having AD were randomly allocated to two groups. To the first group, evening primrose oil was supplied as 500-mg oval clear unmarked capsules, while placebo capsules identical in appearance and containing 300 mg of sunflower oil were given to the other group. Treatment continued for a period of 5 months. With pre-designed scoring system (based on four major parameters: extent, intensity, itching, and dryness), clinical evaluation was done at baseline and subsequent monthly visits. Data of the first 25 patients from each group who completed the 5 months of trial were compiled and analyzed. RESULTS: At the end of the fifth month, 24 (96%) patients of EPO group and 8 (32%) patients of placebo group showed improvement. There was significant difference in outcome of treatment between two groups (P<0.00001). No significant adverse effect was reported by any patient/guardian at any point of assessment. CONCLUSION: Evening primrose oil is a safe and effective medicine in management of AD. However, since not all researchers across the world have found the same good result, further large trials on Indian patients are needed.
机译:背景:特应性皮炎(AD)是一种多因素起源的慢性复发性瘙痒性皮肤病,通常始于儿童时期。据报道,必需脂肪酸的代谢缺陷导致促炎性前列腺素(PGE2和PGF2)相对占优势,是AD发病的重要因素。月见草油(EPO)作为γ-亚麻酸(GLA)的来源已引起AD管理。目的:评估EPO在我们的患者特应性皮炎中的疗效和安全性。方法:在加尔各答的一家转诊医院,将临床连续诊断为患有AD的连续新门诊患者(OPD)随机分为两组。对于第一组,月见草油以500 mg椭圆形透明无标记胶囊的形式提供,而另一组则给予外观相同且含有300 mg葵花籽油的安慰剂胶囊。治疗持续了5个月。使用预先设计的评分系统(基于四个主要参数:程度,强度,瘙痒和干燥度),在基线和随后的每月就诊时进行临床评估。收集并分析了完成每组5个月试验的每组前25名患者的数据。结果:在第五个月末,EPO组24例(96%)患者和安慰剂组8例(32%)患者表现出改善。两组之间的治疗结果有显着差异(P <0.00001)。任何患者/监护人在任何评估点均未报告明显的不良反应。结论:月见草油是治疗AD的一种安全有效的药物。但是,由于并非所有的研究人员都发现了同样好的结果,因此需要对印度患者进行进一步的大型试验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号